BioSmart Fact File 285.1 orbitbiotech acetheraceonline A new product named KiCoPen has been developed by the Cambridge Consultants. This new injection pen design allows patients to easily self-manage their treatment, while ensuring they’re getting the exact amount of insulin they need. This is an injection pen for diabetes patients which aim to make daily management of the disease an easier and more accurate task. The KiCoPen device is designed to capture the exact dose delivered and send the information to an associated Smartphone app. And all without a battery the action of removing the injector cap powers the device. There is currently no injector pen in the market that combines these capabilities. Current market offerings allow patients to know when the last insulin dose was given by freezing the time the cap was taken off the pen. This, however, leaves room for error if the cap falls off accidentally, providing false confirmation that the dose was taken. By being able to confirm the actual injection event and the exact dose of insulin delivered and deducing the time it was delivered via the Smartphone, KiCoPen allows the patient to be confident that they are on track with their daily insulin regimen. This in turn improves patient’s compliance and results in better glycaemic control which helps in reducing late-stage complications. It also proves to manufacturers that such an innovative, low-cost design can also be applied to pre-filled pens.
Posted on: Wed, 26 Nov 2014 04:52:22 +0000
Trending Topics
Recently Viewed Topics
© 2015